Active Biotech Year End Report 2023


  • Lead Principal Investigator Rebekka Schneider-Kramann presents the clinical plan and positioning of tasquinimod in myelofibrosis (December 1)
  • Active Biotech enters into collaboration agreement for clinical ocular biodistribution study with laquinimod (December 5)
  • Active Biotech announces outcome of the Company’s rights issue (December 6)
  • Preclinical data of tasquinimod presented at ASH (December 14)
  • Active Biotech provides update on the scheduled clinical program for 2024 (December 22)


  • Active Biotech confirmed positive clinical safety profile of laquinimod eye drops (January 30)
  • Safety and preliminary efficacy of naptumomab in combination with durvalumab presented at AACR 2023 (April 19)
  • Positive interim data from the ongoing study of tasquinimod in heavily pre-treated patients with relapsed and refractory multiple myeloma presented at ASCO 2023 (May 26)
  • Positive safety and tolerability in clinical phase I study and preclinical ocular biodistribution data supporting the further development of laquinimod eye drops for inflammatory eye diseases were established (May 30)
  • New preclinical data regarding tasquinimod’s anti-fibrotic effects in myelofibrosis were presented at EHA 2023 (June 10)
  • Collaboration agreement for clinical study with tasquinimod in myelofibrosis signed (July 31)
  • Tasquinimod successfully completed dose optimization in patients with multiple myeloma and advances into the pre-planned expansion cohort (September 11)
  • Clinical safety and preclinical ocular biodistribution for laquinimod eye drops presented at the IOIS meeting is made available on Active Biotech’s website (September 13)


SEK M Oct-Dec Jan-Dec
2023 2022 2023 2022
Net sales
Operating profit/loss -12.8 -15.2 -46.5 -57.9
Profit/loss after tax -12.5 -15.0 -45.8 -58.4
Earnings per share (SEK) -0.04 -0.06 -0.17 -0.25
Cash and cash equivalents
(at close of period)
36.2 41.8

The report is also available at

This information was provided to the media, through the agency of the contact persons set out below, for publication on February 8, 2024 at 08.30 CET.